Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News about ARMP centers on its late clinical-stage phage pipeline, including AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa, FDA designations and regulatory interactions, scientific publications on phage structure, and clinical program updates.
Company updates also cover financial results, research and development spending, grant-supported program activity, credit agreement and warrant amendments with Innoviva-related entities, and board or annual-meeting governance matters. Armata describes in-house phage-specific cGMP manufacturing as part of its development model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Armata Pharmaceuticals, a biotechnology firm focused on bacteriophage therapeutics, announced its fourth-quarter and full-year 2022 financial results on March 16, 2023. Key highlights include positive topline results from the SWARM-P.a. Phase 1b/2a trial for AP-PA02 in cystic fibrosis patients, which supports its progression to Phase 2b. The company also initiated the Phase 2 study for non-cystic fibrosis bronchiectasis and advanced its AP-SA02 program. Financially, Armata reported Q4 2022 grant revenue of $1.1 million and a loss from operations of $10.3 million, an increase from the previous year. The company concluded the year with $14.9 million in cash.